Latin name:
NEMOZOLE
Active substance:
albendazole
Release form Nemozole:
film-coated tablets
Owner / Registrar Nemozole:
IPCA LABORATORIES, Ltd.
International Classification of Diseases (ICD-10) A07.1
Giardiasis [giardiasis] B67
Echinococcosis B69
Cysticercosis B76
Hookworm B76.1
Necatorosis B77
Ascariasis B78
Strongyloidiasis B79
Trichurosis B80
Enterobiasis
Pharmacological group Nemozole:
Anthelmintic drug
pharmachologic effect Nemozole:
Antihelminthic drug Nemozole with antiprotozoal effect. The main mechanism of the drug of action is associated with an inhibitory effect on beta-tubulin polymerization. Which leads to the destruction of the cytoplasmic microtubules of the cells of the intestinal tract of helminths. The drug Nemosole changes the course of biochemical processes (suppresses the utilization of glucose), blocks the movement of secretory granules and other organelles in the muscle cells of roundworms and helps them die. The drug is most active against larval forms of cestodes - Echinococcus granulosus and Taenia solium, nematodes - Strongyloides stercolatis.
After oral administration, it is poorly absorbed from the gastrointestinal tract, unchanged is not detected in blood plasma. Oral bioavailability is low, about 30%. Reception simultaneously with fatty foods increases absorption and the value of C max in blood plasma by 5 times.
Metabolism and excretion Nemozole:
Albendazole is rapidly biotransformed in the liver into the primary metabolite, albendazole sulfoxide, which also has anthelmintic activity. C max of albendazole sulfoxide in blood plasma is achieved in the interval from 2 to 5 hours, binding to plasma proteins is 70%. Albendazole sulfoxide is almost completely distributed throughout the body; found in urine, bile, liver, in the wall of the cyst and cystic fluid, cerebrospinal fluid.
Albendazole sulfoxide is converted in the liver to albendazole sulfone (a secondary metabolite) and other oxidized products. T 1/2 of albendazole sulfoxide - 8-12 hours. It is excreted in the form of various metabolites in the urine.
Pharmacokinetics in special clinical situations Excretion of albendazole and its main metabolite does not change with impaired renal function.
In patients with impaired liver function, bioavailability increases, C max of albendazole sulfoxide in blood plasma increases by 2 times, T 1/2 is lengthened. Albendazole is an inducer of microsomal enzymes of the cytochrome P450 system; accelerates the metabolism of many drugs Nemozole.
From the digestive system: abnormal liver function with changes in liver function tests (mild or moderate increase in transaminase activity), abdominal pain, nausea, vomiting.
From the hematopoietic system: leukopenia, granulocytopenia, agranulocytosis, thrombocytopenia, pancytopenia.
From the side of the central nervous system: headache, dizziness, meningeal symptoms.
Dermatological reactions: reversible alopecia, skin rash, itching.
Others: fever, increased blood pressure, acute renal failure, allergic reactions.
Overdose Nemozole:
Treatment: gastric lavage, activated carbon. If necessary, symptomatic therapy is performed.
special instructions
With neurocysticercosis, appropriate therapy with GCS and anticonvulsants should be carried out. GCS for oral administration or intravenous administration is used to prevent a hypertensive attack in the first week of anticyst therapy.
Control of laboratory parameters
While using the drug Nemozole, it is recommended to monitor the cellular composition of the blood. If leukopenia occurs, therapy is stopped.
Blood tests should be performed at the beginning of each 28-day cycle every 2 weeks during albendazole therapy. It is possible to continue treatment with albendazole if the decrease in the total content of leukocytes and neutrophilic leukocytes is moderate and does not progress.
In case of liver dysfunction Use with caution in case of liver dysfunction (before and during treatment, liver function should be monitored regularly).
Application during pregnancy and lactation
The drug Nemozole is contraindicated for use during pregnancy. If it is necessary to prescribe the drug during lactation, the issue of stopping breastfeeding should be resolved.
Before prescribing the drug Nemozole, a pregnancy test should be performed in women of childbearing age . During the period of therapy, reliable methods of contraception should be used.
Drug interactions Nemozole:
When used together with albendazole, dexamethasone and cimetidine increase the concentration of albendazole sulfoxide in the blood.
How to take Nemozole:
The average therapeutic dose for the treatment of nematodes for adults and children over 2 years of age is 400 mg or 20 ml of the suspension orally once.
The drug Nemozole is taken with meals. It is recommended that all family members be treated simultaneously.
For neurocysticercosis and echinococcosis, patients weighing 60 kg or more are prescribed 400 mg 2 times / day; with a body weight of less than 60 kg, the dose is set at the rate of 15 mg / kg / day in 2 divided doses.
The maximum daily dose is 800 mg (400 mg 2 times / day). The course of treatment for neurocysticercosis is 8-30 days; with echinococcosis - 3 cycles of 28 days with a 14-day interval between cycles.
With giardiasis, the drug Nemozole is prescribed for children at the rate of 10-15 mg / kg 1 time / day for 5-7 days.
With toxocariasis, adults and children over 14 years old with a body weight of more than 60 kg are prescribed 400 mg 2 times / day; with a body weight of less than 60 kg - 200 mg 2 times / day; for children under 14 years of age, the dose is set at the rate of 10 mg / kg 2 times / day. The duration of therapy is 7-14 days.
Storage conditions and shelf life:
List B. The drug Nemozole should be stored out of the reach of children, dry, protected from light at a temperature not exceeding 25 ° C.
The shelf life Nemozole is 3 years.
Dispensing from pharmacies Nemozole:
